AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03710603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade
Description: Bortezomib will be given at a dose of 1.3 mg/m2 SC twice a week (Days 1, 4, 8, and 11) in Cycles 1-6; four 28-day induction cycles (Cycles 1 to 4), and two 28-day consolidation cycles (Cycles 5-6). Subjects will not receive bortezomib after Cycle 6. On treatment days when both bortezomib and daratumumab are administered, bortezomib must be administered after the daratumumab administration.
Study NCT03503331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [C-11]PiB-PET/MRI
Description: All study participants will undergo brain imaging with \[C-11\]PiB-PET/MRI. \[C-11\]PiB is a PET imaging agent used primarily to measure the amount of abnormal protein (called beta-amyloid) in the brain. The investigator will also use this tracer to evaluate regional cerebral blood flow.
Study NCT03710603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered PO at 25 mg on Days 1 to 21 in Cycles 1-6; four 28-day induction cycles and two 28-day consolidation cycles. Following consolidation, subjects will then start maintenance therapy, during which they will receive lenalidomide 10 mg daily PO on Days 1 to 28 (continuously) of each 28-day cycle until disease progression or unacceptable toxicity. After 3 cycles of maintenance therapy, if well tolerated, the lenalidomide dose may be increased to 15 mg daily, at the discretion of the investigator.
Study NCT03710603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide will be administered PO at 25 mg on Days 1 to 21 in Cycles 1-6; four 28-day induction cycles and two 28-day consolidation cycles. Following consolidation, subjects will then start maintenance therapy, during which they will receive lenalidomide 10 mg daily PO on Days 1 to 28 (continuously) of each 28-day cycle until disease progression or unacceptable toxicity. After 3 cycles of maintenance therapy, if well tolerated, the lenalidomide dose may be increased to 15 mg daily, at the discretion of the investigator.
Study NCT03710603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Dexamethasone will be administered PO at 40 mg daily on Days 1-4 and Days 9-12 of each 28-day cycle during induction and consolidation (Cycles 1-6). On daratumumab administration days, during induction/consolidation, dexamethasone may be administered intravenously 1 hour before the daratumumab administration. On days when daratumumab is not administered, dexamethasone is administered PO. Dexamethasone tablets are to be taken with or immediately after a meal or snack, preferably in the morning.
Study NCT03710603 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: Dexamethasone will be administered PO at 40 mg daily on Days 1-4 and Days 9-12 of each 28-day cycle during induction and consolidation (Cycles 1-6). On daratumumab administration days, during induction/consolidation, dexamethasone may be administered intravenously 1 hour before the daratumumab administration. On days when daratumumab is not administered, dexamethasone is administered PO. Dexamethasone tablets are to be taken with or immediately after a meal or snack, preferably in the morning.
Study NCT02469831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Study NCT00149656 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamins
Description: dietary supplement of multivitamins
Study NCT00149656 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Selenium
Description: dietary supplement of selenium only
Study NCT00149656 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pill
Study NCT00793702 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rdESAT-6 + rCFP-10
Description: rdESAT-6 + rCFP-10 skin test administered intradermally by the mantoux injection technique
Study NCT03732794 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AtriCure CryoICE & AtriClip LAA Exclusion
Description: AtriCure CryoICE system in performing the Cox-Maze III lesion set, in conjunction with LAA exclusion using the AtriClip device.
Study NCT03366259 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 200Mcg Tab
Description: administration of 200 Mcg of misoprotol rectal
Study NCT03366259 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: elective cesarean section
Description: elective cesarean section for full term patients
Study NCT03366259 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: elective cesarean section
Description: elective cesarean section for full term patients
Study NCT02255656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alemtuzumab GZ402673
Description: Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
Study NCT02941055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fiber diet
Description: Foods will be delivered with a home delivery chain once a week for 10 wks of each diet
Study NCT02941055 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protein diet
Description: Foods will be delivered with a home delivery chain once a week for 10 wks of each diet
Study NCT04049474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ERBOKRYO® CA - Cryosurgical Unit with Flexible ERBECRYO Probe, 1.9 mm outer diameter (ERBE Inc., Tubingen, Germany)
Description: See BCI description.
Study NCT01934972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CR + DCS (D-cycloserine)
Description: CR + DCS
Study NCT01934972 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CR + placebo
Description: CR + placebo
Study NCT02976922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic lozenge
Description: 10 patients with RAS are randomised to active treatment with probiotic lozenge, one lozenge twice daily for 3 months and other 10 patients with RAS are randomised to treatment with placebo lozenge, one lozenge twice daily for 3 months.
Study NCT03189719 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
Study NCT03189719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to pembrolizumab (saline) administered IV Q3W on Day 1 of each 3-week cycle, up to 35 administrations.
Study NCT03189719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle. Duration of cisplatin treatment will be capped at 6 doses.
Study NCT03189719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 80 mg/m\^2 administered IV Q3W on Day 1 of each 3-week cycle. Duration of cisplatin treatment will be capped at 6 doses.
Study NCT03189719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 800 mg/m\^2/day (4000 mg/m\^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each 3-week cycle, or per local standard for 5-FU administration, up to 35 administrations.
Study NCT02976922 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic lozenge
Description: 10 patients with RAS are randomised to active treatment with probiotic lozenge, one lozenge twice daily for 3 months and other 10 patients with RAS are randomised to treatment with placebo lozenge, one lozenge twice daily for 3 months.
Study NCT03864770 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Description: Extracorporeal shock wave therapy is a mechanical sound wave that generates energy by extremely high-frequency vibration to compress the medium. Low-energy extracorporeal shock waves can be used for cell regeneration and pain control therapy; medium-high energy can be used to treat patients with poor bone healing; high-energy can be used to lithotrite. In recent years, extracorporeal shock waves have been applied on the musculoskeletal diseases, such as: epicondylitis, plantar fasciitis, chronic pelvic pain, chronic heel pain syndrome, lymphedema, burns, pressure sores, calcific tendinitis and myofascial pain syndrome. This treatment is a non-invasive and safe treatment.
Study NCT03864770 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General physical therapy
Description: The general physical therapies such as: thermotherapy, straight leg raise (SLR), transcutaneous electrical nerve stimulation (TENS) for treatment on calf muscle.
Study NCT03864770 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General physical therapy
Description: The general physical therapies such as: thermotherapy, straight leg raise (SLR), transcutaneous electrical nerve stimulation (TENS) for treatment on calf muscle.
Study NCT03890315 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Functional MRI
Description: In fMRI, patients will first be taking a resting state phase in case of activations. In the block design phase, they will be given tactile stimuli in affected extremity, and then healthy extremity in 3 blocks, followed by pauses.~Primary and secondary sensorial cortex, insular cortex, anterior cingulate cortex, preforntal cortex and amygdala activation will be chosen as regions of interest, and their activation will be recorded for analyses.
Study NCT01578070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.2μg Act-HIB®
Description: 0.2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
Study NCT01578070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ViscoGel® and 0.2μg Act-HIB®
Description: Pre-selected dose of ViscoGel® (from phase A) and Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
Study NCT01578070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ViscoGel® and 2μg Act-HIB®
Description: Pre-selected dose of ViscoGel® (from phase A) and 2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
Study NCT01578070 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2μg Act-HIB®
Description: 2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
Study NCT01578070 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 10μg Act-HIB®
Description: Clinical standard dose of 10μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
Study NCT03358797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention-control
Description: Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting,and women's health topics
Study NCT03358797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community based intervention with resilience training
Description: Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting, and women's health topics. In addition, there will be content targeting resilience training including: positive emotions, cognitive flexibility, life meaning, and active coping strategies.
Study NCT03358797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intervention-HPP
Description: Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting,and women's health topics. In addition, there will be training in leadership skills, community interventions, community needs assessment, intervention planning and outcomes assessment.
Study NCT03358797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pilot
Description: Lifestyle intervention with presentations by multiple professionals (nutritionists, exercise trainers, and psychotherapists), this intervention will include Mediterranean diet education, physical activity, social support, food tasting and cooking, goal setting, and women's health topics. In addition, there will be content targeting resilience training including: positive emotions, cognitive flexibility, life meaning, and active coping strategies.
Study NCT04569253 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TempSure
Description: Non-invasive radiofrequency treatments
Study NCT05744908 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pentosan Polysulphate
Description: 300mg 3 times a day
Study NCT04141046 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XCSITE100 Stimulator - Individualized theta-tACS
Description: 20 second ramp-in and ramp-out with 40 minutes of stimulation for a total of 2440 seconds of stimulation
Study NCT04141046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XCSITE100 Stimulator - Individualized alpha-tACS
Description: 20 second ramp-in and ramp-out with 40 minutes of stimulation for a total of 2440 seconds of stimulation
Study NCT04141046 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: XCSITE100 Stimulator - Active Sham
Description: 20 seconds of ramp-in to 40 seconds of 10 Hz tACS with a ramp out of 20 seconds for a total of 80 seconds of stimulation
Study NCT04356742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Dapagliflozin 10mg, orally, once daily, up to 24weeks
Study NCT04356742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dapagliflozin Placebo, orally, once daily, up to 24weeks
Study NCT04356742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evogliptin 5mg
Description: Evogliptin 5mg, orally, once daily for background therapy
Study NCT04356742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Evogliptin 5mg
Description: Evogliptin 5mg, orally, once daily for background therapy
Study NCT04356742 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin≥1000mg
Description: Metformin≥1000mg, orally, daily for background therapy
Study NCT04356742 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin≥1000mg
Description: Metformin≥1000mg, orally, daily for background therapy
Study NCT00304239 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Metvix-PDT
Description: Metvix 160 mg/g Cream was applied for 3 hours with occlusive dressing, and illumination with non-coherent red light using the Aktilite CL128 lamp, with a total light dose 37 Joule/square centimeter (J/cm²). All eligible lesions on the participant were treated twice with an interval of 1 week between treatments.
Study NCT00304239 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle-PDT
Description: Vehicle Cream was applied for 3 hours with occlusive dressing, and illumination with non-coherent red light using the Aktilite CL128 lamp, with a total light dose 37 J/cm². All eligible lesions on the participant were treated twice with an interval of 1 week between treatments.
Study NCT02902068 — intervention group
Intervention type: DEVICE
Intervention: NICaS Bio Impedance
Description: Hemodynamic monitoring will be carried out using non invasive NICaS cardiac impedance by the use of two electrodes stickers which are pasted on the wrists for about 6 minutes.~Monitoring will be done with women lying down or sitting up half an hour preoperatively (in the woman's surgery waiting room) intraoperatively, and postoperatively in the PACU.~Preoperative data will be compared to intraoperative and postoperative data, and will be analyzed in order to evaluate the dynamic cardiac output changes in women undergoing cesarean sections.
Study NCT04288752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR101 Lubricating Intravaginal Ring
Description: VR101 Lubricating Intravaginal Ring is a personal lubrication device, for vaginal application, intended to moisturize and lubricate, to enhance the ease and comfort of intimate sexual activity, and supplement the body's natural lubrication.
Study NCT04288752 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Ring
Description: Sham rings are visually identical to VR101 Lubricating Intravaginal Rings, but no lubricating solution was added.
Study NCT01807039 — intervention group
Intervention type: PROCEDURE
Intervention: hip fracture surgery
Description: we evaluate the relationship between the monitored parameters and 30 day survival
Study NCT03939754 — intervention group
Intervention type: BEHAVIORAL
Intervention: Dedalo project
Description: Physical activity, healthy food, socialization and mental activity promotion
Study NCT02759497 — intervention group
Intervention type: OTHER
Intervention: serum amyloid A level
Description: serum amyloid A level (SAA)
Study NCT03189719 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-FU
Description: 800 mg/m\^2/day (4000 mg/m\^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each 3-week cycle, or per local standard for 5-FU administration, up to 35 administrations.
Study NCT03716973 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Density Programming
Description: Patients implanted with Medtronic spinal cord stimulator will have high density programming.
Study NCT02734004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab
Study NCT03098030 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dinutuximab
Description: Dinutuximab injection, for intravenous (IV) use
Study NCT03098030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan injection, IV infusion
Study NCT03098030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan injection, IV infusion
Study NCT03098030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Topotecan for injection
Study NCT03824652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walnuts
Description: 2 ounces of walnuts daily for 4-10 weeks
Study NCT03824652 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual diet
Description: Subject continues usual diet
Study NCT00732524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide
Description: Glipizide XL 10 mg once daily 30 mins before breakfast
Study NCT00732524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide and Glargine
Description: Glipizide XL 10 mg daily 30 minutes before breakfast Insulin Glargine 10 units subcutaneously at bedtime daily
Study NCT03224078 — intervention group
Intervention type: OTHER
Intervention: data extraction
Description: No Special interventions except from data extraction form the respective routine data sources are planned .
Study NCT02825576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Sugammadex 2mg/kg given for reversal agent
Study NCT02825576 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine/Glycopyrrolate
Description: Neostigmine 50 mcg/kg plus Glycopyrrolate 10 mcg/kg given for reversal agent
Study NCT02122614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation (PR) plus PA monitoring and feedback from a pedometer
Description: Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychoeducation sessions (once a week). Patients will also receive a pedometer to self-monitor their PA during and after the PR program and individualized step-count goals.
Study NCT02122614 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation (PR)
Description: Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychoeducation sessions (once a week).
Study NCT01247792 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SOPs for decision-making and communication
Description: Development and implementation of SOPs for timely and interdisciplinary EOL-decisionmaking and a communication strategy with relatives which addresses participants, set-up, time-points, and content
Study NCT00267358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RC-1291 HCl
Study NCT00267358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02926651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Oral TXA (Tranexamic Acid)
Description: Three 650mg tablets of oral TXA 2 hours prior to incision with three 250mg tablets of ascorbic acid (oral TXA placebo) given 6 hours postoperatively and a final 750mg ascorbic acid dose given the morning of postoperative day 1.
Study NCT02926651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multi-Dose Oral TXA (Tranexamic Acid)
Description: Three 650mg tablets of oral TXA 2 hours prior to incision with a second 1950mg oral TXA dose given 6 hours postoperatively and a final 1950mg oral TXA dose given the morning of postoperative day 1.
Study NCT03964363 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unsupervised home-based physical prehabilitation
Description: Subsequent to screening and initial testing for frailty syndrome, participants receive an information booklet containing a selection of exercises, which allows independent prehabilitation at home.
Study NCT02086344 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PBS
Description: TLH plus PBS
Study NCT02086344 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TLH _adnexal preservation
Description: TLH without PBS